Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
This study is ongoing, but not recruiting participants.
Study NCT00004095 Information provided by National Cancer Institute (NCI)
First Received: December 10, 1999 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Breast Cancer
Colorectal Cancer
Kidney Cancer
Lung Cancer
Pancreatic Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma, Renal Cell
Colorectal Neoplasms
Kidney Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Urinary Bladder Neoplasms
More general conditions related to this trial
Adenocarcinoma
Breast Diseases
Carcinoma
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Kidney Diseases
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Pancreatic Diseases
Rectal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
gemcitabine hydrochloride
irinotecan hydrochloride
Additional drug interventions recognized in this trial
Camptothecin
Gemcitabine
Irinotecan
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
